{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T19:06:25Z","timestamp":1790795185138,"version":"4.1.0"},"reference-count":28,"publisher":"Japan Atherosclerosis Society","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Atheroscler Thromb","JAT"],"published-print":{"date-parts":[[2018,6,1]]},"DOI":"10.5551\/jat.44412","type":"journal-article","created":{"date-parts":[[2018,4,6]],"date-time":"2018-04-06T18:19:45Z","timestamp":1523038785000},"page":"521-538","source":"Crossref","is-referenced-by-count":138,"title":["Efficacy and Safety of Pemafibrate Versus Fenofibrate in Patients with High Triglyceride and Low HDL Cholesterol Levels: A Multicenter, Placebo-Controlled, Double-Blind, Randomized Trial"],"prefix":"10.5551","volume":"25","author":[{"given":"Hidenori","family":"Arai","sequence":"first","affiliation":[{"name":"National Center for Geriatrics and Gerontology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shizuya","family":"Yamashita","sequence":"additional","affiliation":[{"name":"Department of Community Medicine and Department of Cardiovascular Medicine, Osaka University Graduate School of Medicine"},{"name":"Rinku General Medical Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koutaro","family":"Yokote","sequence":"additional","affiliation":[{"name":"Department of Diabetes, Metabolism and Endocrinology, Chiba University Graduate School of Medicine"},{"name":"Department of Clinical Cell Biology and Medicine, Chiba University Graduate School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eiichi","family":"Araki","sequence":"additional","affiliation":[{"name":"Department of Metabolic Medicine, Faculty of Life Sciences, Kumamoto University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideki","family":"Suganami","sequence":"additional","affiliation":[{"name":"Clinical Data Science Department, Kowa Company, Ltd."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shun","family":"Ishibashi","sequence":"additional","affiliation":[{"name":"Division of Endocrinology and Metabolism, Department of Medicine, Jichi Medical University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"on behalf of the K-877 Study Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3489","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1) Fulcher J, O'Connell R, Voysey M, Emberson J, Blackwell L, Mihaylova B, Simes J, Collins R, Kirby A, Colhoun H, Braunwald E, La Rosa J, Pedersen TR, Tonkin A, Davis B, Sleight P, Franzosi MG, Baigent C and Keech A: Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials. Lancet, 2015; 385: 1397-1405","DOI":"10.1016\/S0140-6736(14)61368-4"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2) Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, Kuder JF, Wang H, Liu T, Wasserman SM, Sever PS and Pedersen TR: Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. N Engl J Med, 2017; 376: 1713-1722","DOI":"10.1056\/NEJMoa1615664"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) Fruchart JC: Pemafibrate (K-877), a novel selective peroxisome proliferator-activated receptor alpha modulator for management of atherogenic dyslipidaemia. Cardiovasc Diabetol, 2017; 16: 124","DOI":"10.1186\/s12933-017-0602-y"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4) National Cholesterol Education Program (NCEP) Expert Panel on Detection E, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III): Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation, 2002; 106: 3143-3421","DOI":"10.1161\/circ.106.25.3143"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5) Staels B, Dallongeville J, Auwerx J, Schoonjans K, Leitersdorf E and Fruchart JC: Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation, 1998; 98: 2088-2093","DOI":"10.1161\/01.CIR.98.19.2088"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6) Loomba RS and Arora R: Prevention of cardiovascular disease utilizing fibrates--a pooled meta-analysis. Am J Ther, 2010; 17: e182-188","DOI":"10.1097\/MJT.0b013e3181dcf72b"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7) Rosenson RS: Fenofibrate: treatment of hyperlipidemia and beyond. Expert Rev Cardiovasc Ther, 2008; 6: 1319-1330","DOI":"10.1586\/14779072.6.10.1319"},{"key":"8","unstructured":"8) Feingold K and Grunfeld C: Triglyceride Lowering Drugs. In: Endotext, ed by De Groot LJ, Chrousos G, Dungan K, Feingold KR, Grossman A, Hershman JM, Koch C, Korbonits M, McLachlan R, New M, Purnell J, Rebar R, Singer F, and Vinik A, MDText.com, Inc., South Dartmouth (MA), 2017"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9) Wang D, Liu B, Tao W, Hao Z and Liu M: Fibrates for secondary prevention of cardiovascular disease and stroke. Cochrane Database Syst Rev, 2015; Cd009580","DOI":"10.1002\/14651858.CD009580.pub2"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10) Bruckert E, Labreuche J, Deplanque D, Touboul PJ and Amarenco P: Fibrates effect on cardiovascular risk is greater in patients with high triglyceride levels or atherogenic dyslipidemia profile: a systematic review and meta-analysis. J Cardiovasc Pharmacol, 2011; 57: 267-272","DOI":"10.1097\/FJC.0b013e318202709f"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11) Ginsberg HN, Elam MB, Lovato LC, Crouse JR 3rd, Leiter LA, Linz P, Friedewald WT, Buse JB, Gerstein HC, Probstfield J, Grimm RH, Ismail-Beigi F, Bigger JT, Goff DC Jr., Cushman WC, Simons-Morton DG and Byington RP: Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med, 2010; 362: 1563-1574","DOI":"10.1056\/NEJMoa1001282"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12) Ahmad J, Odin JA, Hayashi PH, Chalasani N, Fontana RJ, Barnhart H, Cirulli ET, Kleiner DE and Hoofnagle JH: Identification and Characterization of FenofibrateInduced Liver Injury. Dig Dis Sci, 2017; 62: 3596-3604","DOI":"10.1007\/s10620-017-4812-7"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13) Davidson MH, Armani A, McKenney JM and Jacobson TA: Safety considerations with fibrate therapy. Am J Cardiol, 2007; 99: 3c-18c","DOI":"10.1016\/j.amjcard.2006.11.016"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14) National Kidney Foundation: KDOQI Clinical Practice Guideline for Diabetes and CKD: 2012 Update. Am J Kidney Dis, 2012; 60: 850-886","DOI":"10.1053\/j.ajkd.2012.07.005"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15) Ferri N, Corsini A, Sirtori C and Ruscica M: PPAR-alpha agonists are still on the rise: an update on clinical and experimental findings. Expert Opin Investig Drugs, 2017; 26: 593-602","DOI":"10.1080\/13543784.2017.1312339"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16) Fruchart JC: Selective peroxisome proliferator-activated receptor \u03b1 modulators (SPPARM\u03b1): the next generation of peroxisome proliferator-activated receptor \u03b1-agonists. Cardiovasc Diabetol, 2013; 12: 82","DOI":"10.1186\/1475-2840-12-82"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17) Raza-Iqbal S, Tanaka T, Anai M, Inagaki T, Matsumura Y, Ikeda K, Taguchi A, Gonzalez FJ, Sakai J and Kodama T: Transcriptome Analysis of K-877 (a Novel Selective PPAR\u03b1 Modulator (SPPARM\u03b1))-Regulated Genes in Primary Human Hepatocytes and the Mouse Liver. J Atheroscler Thromb, 2015; 22: 754-772","DOI":"10.5551\/jat.28720"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18) Yamazaki Y, Abe K, Toma T, Nishikawa M, Ozawa H, Okuda A, Araki T, Oda S, Inoue K, Shibuya K, Staels B and Fruchart JC: Design and synthesis of highly potent and selective human peroxisome proliferator-activated receptor alpha agonists. Bioorg Med Chem Lett, 2007; 17: 4689-4693","DOI":"10.1016\/j.bmcl.2007.05.066"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19) Ishibashi S, Arai H, Yokote K, Araki E, Suganami H and Yamashita S: Efficacy and safety of pemafibrate (K-877), a selective peroxisome proliferator-activated receptor \u03b1 modulator, in patients with dyslipidemia: Results from a 24-week, randomized, double blind, active-controlled, phase 3 trial. J Clin Lipidol, 2018; 12: 173-184","DOI":"10.1016\/j.jacl.2017.10.006"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20) Ishibashi S, Yamashita S, Arai H, Araki E, Yokote K, Suganami H, Fruchart JC and Kodama T: Effects of K-877, a novel selective PPAR\u03b1 modulator (SPPARM\u03b1), in dyslipidaemic patients: A randomized, double blind, active- and placebo-controlled, phase 2 trial. Atherosclerosis, 2016; 249: 36-43","DOI":"10.1016\/j.atherosclerosis.2016.02.029"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21) Sairyo M, Kobayashi T, Masuda D, Kanno K, Zhu Y, Okada T, Koseki M, Ohama T, Nishida M, Sakata Y and Yamashita S: A Novel Selective PPAR\u03b1 Modulator (SPPARM\u03b1), K-877 (Pemafibrate), Attenuates Postprandial Hypertriglyceridemia in Mice. J Atheroscler Thromb, 2018; 25: 142-152","DOI":"10.5551\/jat.39693"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22) Masuda D and Yamashita S: Postprandial Hyperlipidemia and Remnant Lipoproteins. J Atheroscler Thromb, 2017; 24: 95-109","DOI":"10.5551\/jat.RV16003"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23) Davidson MH, Rosenson RS, Maki KC, Nicholls SJ, Ballantyne CM, Mazzone T, Carlson DM, Williams LA, Kelly MT, Camp HS, Lele A and Stolzenbach JC: Effects of fenofibric acid on carotid intima-media thickness in patients with mixed dyslipidemia on atorvastatin therapy: randomized, placebo-controlled study (FIRST). Arterioscler Thromb Vasc Biol, 2014; 34: 1298-1306","DOI":"10.1161\/ATVBAHA.113.302926"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24) Arai H, Yamashita S, Yokote K, Araki E, Suganami H and Ishibashi S: Efficacy and safety of K-877, a novel selective peroxisome proliferator-activated receptor \u03b1 modulator (SPPARM\u03b1), in combination with statin treatment: Two randomised, double-blind, placebo-controlled clinical trials in patients with dyslipidaemia. Atherosclerosis, 2017; 261: 144-152","DOI":"10.1016\/j.atherosclerosis.2017.03.032"},{"key":"25","unstructured":"25) Hata Y, Goto Y and Itakura H: Clinical assessment of GRS-001 (fenofibrate) in hyperlipidemic patients\u2014a double blind, comparative study, using bezafibrate sustainedrelease tablet as a control drug. Geriatr Med, 1995; 33: 765-822"},{"key":"26","unstructured":"26) Saito Y, Goto Y, Yasugi T, Hata Y, Itakura H, Nakaya N, Tsushima M, Kawakami Y, Kondo T, Ide H, Yachi A, Kihara A, Yamada H, Onodera K, Kanazawa T, Maruhama Y, Ninomiya K, Masamune O, Inomata S, Toyoda T, Oikawa S, Kotake H, Naito T, Murata K, Kawazu S, Tomono S, Hayashi R, Kawakami M, Yamamoto T, Nakamura H, Nishiwaki M, Yoshida S, Fujioka T, Saito E, Kanmatsuse K, Kurokawa K, Teramoto T, Kato H, Kinoshita M, Yazaki Y, Yamada N, Shimano H, Murase T, Miyazaki S, Mashiko S, Numano F, Kishi Y, Nakamura Y, Hirose N, Nagano M, Ishikawa T, Tada N, Tanaka Y, Tamachi H, Shiina Y, Honma Y, Iori S, Handa K, Yoshimura K, Shibata A, Izumi T, Masani F, Muto Y, Noma A, Seishima M, Kuzuya F, Yoshimine N, Fujinami T, Sakuma N, Hamazaki T, Taki H, Takeda R, Mabuchi H, Koizumi J, Sekimoto H, Rin K, Miyabo S, Nakai T, Tamai T, Oida K, Shigeta Y, Hidaka H, Kita T, Nagano Y, Nakagawa M, Sasaki S, Yasunaga K, Tetsutani T, Osawa N, Takamatsu J, Morii H, Nishizawa Y, Matsuzawa Y, Kubo M, Yamamoto A, Yamamura T, Nomoto H, Yukawa S, Maeda T, Ishikawa H, Nonaka H, Yokoyama M, Ishikawa Y, Kasuga M, Yoshino G, Kazumi T, Kimura I, Ishioka T, Kibata M, Kamisaka K, Kajiyama G, Horiuchi I, Ishikawa K, Kusukawa R, Okuda F, Hiwada K, Sekiya T, Suehiro T, Fujishima M, Yoshinari M, Takeshita A, Sunagawa K, Arakawa K, Sasaki J, Matsunaga A, Toshima H, Hashimoto R, Nagataki S, Akasawa S, Shichiri M, Kobori S, Tanaka N, Takesako K, Mimura G, Higa S: Clinical assessment of GRS-001 (fenofibrate) in hyperlipidemic patients\u2014a dose finding, double blind study. Prog Med, 1995; 15 (Suppl 1): 949-1010 [in Japanese]"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27) Blair HA: Pemafibrate: First Global Approval. Drugs, 2017; 77: 1805-1810","DOI":"10.1007\/s40265-017-0818-x"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28) Keech A, Simes RJ, Barter P, Best J, Scott R, Taskinen MR, Forder P, Pillai A, Davis T, Glasziou P, Drury P, Kesniemi YA, Sullivan D, Hunt D, Colman P, d'Emden M, Whiting M, Ehnholm C and Laakso M; FIELD study investigators: Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet, 2005; 366: 1849-1861","DOI":"10.1016\/S0140-6736(05)67667-2"}],"container-title":["Journal of Atherosclerosis and Thrombosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jat\/25\/6\/25_44412\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,14]],"date-time":"2019-10-14T11:59:30Z","timestamp":1571054370000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jat\/25\/6\/25_44412\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6,1]]},"references-count":28,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.5551\/jat.44412","relation":{},"ISSN":["1340-3478","1880-3873"],"issn-type":[{"value":"1340-3478","type":"print"},{"value":"1880-3873","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,6,1]]}}}